US Patent

US12156917 — CNP prodrugs with carrier attachment at the ring moiety

Method of Use · Assigned to Ascendis Pharma Growth Disorders AS · Expires 2037-01-05 · 11y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects CNP prodrugs with a carrier attached to the ring moiety, and their uses in treating diseases.

USPTO Abstract

The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-4425`	—
`U-4425`	—
`U-4425`	—

Patent Metadata

Patent number: US12156917
Jurisdiction: US
Classification: Method of Use
Expires: 2037-01-05
Drug substance claim: No
Drug product claim: No
Assignee: Ascendis Pharma Growth Disorders AS
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.